Email Us
Call Us
AUSTIN, Texas – September 15, 2013 – Altogen Labs today detailed its in vivo pharmacology services, covering pharmacokinetics, pharmacodynamics, and biodistribution work that connects a compound’s exposure profile to its observed biological effect.
Efficacy data without exposure data is difficult to act on. A tumor growth delay result tells a sponsor that something happened; a matched PK/PD dataset tells them what concentration produced it, how long it persisted, and what dose to carry into the next study. Regulators expect that link to be established, and partners performing diligence look for it.
Altogen Labs integrates pharmacology endpoints directly into efficacy studies rather than running them as separate programs. Plasma and tissue collection is scheduled against dosing, allowing exposure-response relationships to be built from the same animals that generated the efficacy signal. Biodistribution studies quantify where a compound accumulates, with imaging available for real-time tracking.
Dosing routes supported include intravenous, intraperitoneal, intratumoral, intramuscular, subcutaneous, oral gavage, intranasal, intratracheal, topical, and continuous infusion, using micro-injection techniques and pump-controlled intravenous delivery.
Analytical support includes gene expression analysis by qPCR, protein quantification by automated capillary Western system, ELISA-based biomarker measurement, hematology, histopathology, and immunohistochemistry, delivered with complete raw data and statistical treatment.
About Altogen Labs
Altogen Labs is a preclinical CRO supporting drug development programs across oncology, pharmacology, toxicology, and translational research. The company has extensive experience with xenograft tumor models for preclinical efficacy studies and in vivo toxicology for safety evaluation, with a strong emphasis on high-quality, reproducible study execution and full client ownership of project-specific intellectual property. Altogen Labs works with pharmaceutical, biotechnology, and academic organizations worldwide to evaluate therapeutic candidates in validated in vivo models and generate data for efficacy, safety, PK/PD, pathology, and IND-supporting studies. The company provides integrated preclinical services from early-stage evaluation through advanced development.
Contact Information:
Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com